Education
About Us
Working with TipRanks
Follow Us
CG Oncology, Inc. (CGON)
NASDAQ:CGON
RESEARCH TOOLSreports
CGON Stock Chart & Stats
Day’s Range― - ―
52-Week Range$16.64 - $46.99
Previous Close$30.46
Volume740.02K
Average Volume (3M)915.14K
Market Cap
$1.31B
Enterprise Value$1.44B
Total Cash (Recent Filing)$88.14M
Total Debt (Recent Filing)$16.30M
Price to Earnings (P/E)―
Beta1.84
Next Earnings
May 08, 2025EPS Estimate
-0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.16
Shares Outstanding76,216,860
10 Day Avg. Volume1,209,485
30 Day Avg. Volume915,137
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2674.54
Price to Cash Flow (P/CF)-28.60
P/FCF Ratio0.00
Enterprise Value/Market Cap1.10
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-15.10
Forecast
1Y Price Target
$68.60Price Target Upside298.84% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
---
CG Oncology, Inc. News
See All CGON News
---
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsCretostimogene enters the ring with a landmark 12-month complete response rate of 46% in a trial population of 110 patients, with encouraging durability out to 24 months with no Grade 3 or higher treatment-related adverse events and zero discontinuations due to toxicity.
Market PotentialSuccess in CORE-008 would meaningfully expand the commercial addressable market and support label expansion into BCG-naïve and exposed patients.
Safety ProfileCretostimogene has an excellent safety profile with no treatment-related severe adverse events, enhancing its appeal as a convenient and urologist-friendly therapy.
Bears Say
Competitive PressureTAR-200 has demonstrated a higher anytime complete response rate of 84% compared to cretosmogene in the same setting.
Regulatory RisksRisks to achieving the price target include potential failures in clinical trials, regulatory approval delays, and competitive pressures.
---
Ownership Overview
29.42% Insiders
11.07% Mutual Funds
0.03% Other Institutional Investors
48.06% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CGON FAQ
What was CG Oncology, Inc.’s price range in the past 12 months?
CG Oncology, Inc. lowest stock price was $16.64 and its highest was $46.99 in the past 12 months.
What is CG Oncology, Inc.’s market cap?
CG Oncology, Inc.’s market cap is $1.31B.
When is CG Oncology, Inc.’s upcoming earnings report date?
CG Oncology, Inc.’s upcoming earnings report date is May 08, 2025 which is in 32 days.
How were CG Oncology, Inc.’s earnings last quarter?
CG Oncology, Inc. released its earnings results on Mar 28, 2025. The company reported -$0.46 earnings per share for the quarter, missing the consensus estimate of -$0.345 by -$0.115.
Is CG Oncology, Inc. overvalued?
According to Wall Street analysts CG Oncology, Inc.’s price is currently Undervalued.
Does CG Oncology, Inc. pay dividends?
CG Oncology, Inc. does not currently pay dividends.
What is CG Oncology, Inc.’s EPS estimate?
CG Oncology, Inc.’s EPS estimate is -0.39.
How many shares outstanding does CG Oncology, Inc. have?
CG Oncology, Inc. has 76,216,860 shares outstanding.
What happened to CG Oncology, Inc.’s price movement after its last earnings report?
CG Oncology, Inc. reported an EPS of -$0.46 in its last earnings report, missing expectations of -$0.345. Following the earnings report the stock price went down -1.93%.
Which hedge fund is a major shareholder of CG Oncology, Inc.?
Currently, no hedge funds are holding shares in CGON
---
CG Oncology, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$68.60 (298.84% Upside)
$68.60 (298.84% Upside)
Blogger Sentiment
Bullish
CGON Sentiment 100%
Sector Average 75%
Sector Average 75%
Hedge Fund Trend
Decreased
By 1.7M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $19.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.5%
Last 30 Days ▲ 1.0%
Last 30 Days ▲ 1.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-54.43%
12-Months-Change
Fundamentals
Return on Equity
-19.18%
Trailing 12-Months
Asset Growth
278.72%
Trailing 12-Months
Company Description
CG Oncology, Inc.
CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.
---
CGON Stock 12 Month Forecast
Average Price Target
$68.60
▲(298.84% Upside)
Technical Analysis
FibroBiologics, Inc.
―
Fractyl Health, Inc.
―
Alto Neuroscience, Inc.
―
Kyverna Therapeutics, Inc.
―
Metagenomi, Inc.
―
Best Analysts Covering CGON
1 Year
1 Year Success Rate
0/10 ratings generated profit
1 Year Average Return
-46.51%
reiterated a buy rating 10 days ago
Copying Sam Slutsky's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -46.51% per trade.
---